Drug Discovery Outsourcing Market (By Workflow: Target Identification & Screening, Lead Identification & Candidate Optimization, Target Validation & Functional Informatics, Preclinical Development, Others; By Drug Type: Biologics and Small Molecules; By Therapeutic Area: Oncology, Cardiovascular, Gastrointestinal, Neurology, Respiratory, Others; By Drug Type: Small Molecules and Large Molecules) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug Discovery Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug Discovery Outsourcing Market, by Workflow Type, 2022-2030
8.1.1. Target Identification & Screening
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Lead Identification & Candidate Optimization
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Target Validation & Functional Informatics
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Preclinical Development
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2030)
9.1. Drug Discovery Outsourcing Market, by Therapeutic Area, 2022-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cardiovascular
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Gastrointestinal
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Respiratory
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2019-2030)
10.1. Drug Discovery Outsourcing Market, by Drug Type, 2022-2030
10.1.1. Biologics
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Small Molecules
10.1.2.1. Market Revenue and Forecast (2019-2030)
11.1. North America
11.1.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1. Albany Molecular Research Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. EVOTEC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Laboratory Corporation of America Holdings
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GenScript
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pharmaceutical Product Development, LLC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Charles River
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WuXiAppTec
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Thermo Fisher Scientific Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Dalton Pharma Services
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Oncodesign
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Jubilant Biosys
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. DiscoverX Corporation
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample